glp-1 and type 2 diabetes The activity of GIP for and Obesity GLP-1-based therapies for type 2

doi:10.1016/j.amjmed.2025.01.021 Meloni AR, DeYoung MB, Lowe C, Parkes DG

Metabolic Shift Metabolic rate tends to decrease after discontinuing GLP1, such that the body expends fewer kilojoules in resting and active states

11 This means that only a small fraction of the dose actually reaches the bloodstream, significantly reducing the drugs effectiveness

In 2025, insurance coverage became increasingly restrictive: The rollbacks were happening everywhere at once: Independence Blue Cross stopped covering GLP-1s for weight loss

Experimentation under medical guidance can identify the optimal timing for individual patients

MH is the guarantor of this work and, as such, had full access to data from the study and takes responsibility for the integrity of the data and accuracy of the data analysis